Skip to content

Study · Non-randomized trial · n = 25 · 1997

5 results

A phase II study of leuprolide in advanced/recurrent endometrial cancer.

Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, Franssen E, Roche K

Gynecologic oncology1 Jan 1997Cited by 53 (Europe PMC)

PMID8995560 (opens in a new tab)DOI10.1006/gyno.1996.4544 (opens in a new tab)PepBankPUB-08995560
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In recurrent or metastatic endometrial cancer, no patients responded to leuprolide; 3 of 25 were not evaluable after only 1 treatment.

    In plain wordsIn recurrent or metastatic endometrial cancer, no patients responded to leuprolide.

    Peptide
    Leuprolide
    Outcome
    Not applicableTumor response
    Study

    n = 25

    Outcome group
    Tumor growth · Cancer
    Studied dose
    7.5 mg every 28 days · intramuscularAs given in this study (human).

    Measurements

    Not evaluable for response
    3 patients
    received only 1 treatment

    Source sentences

    Summary
    There were no responders, 8 patients had stable disease for a median 5 months (range 1-8), 14 patients progressed on therapy, and 3 patients were not evaluable for response due to receiving only 1 treatment.
    3 context sentences
    Summary · context
    In order to determine the efficacy and toxicity of the gonadotrophin-releasing hormone agonist Leuprolide in the management of patients with recurrent or metastatic endometrial cancer, we performed a phase II study.
    Summary · context
    Treatment was 7.5 mg i.m. every 28 days, and was to continue for at least 2 courses until evidence of disease progression, patient requested withdrawal, or unacceptable toxicity.
    Summary · context
    Twenty-five patients received Leuprolide for recurrent or metastatic endometrial cancer.
  2. 02HumanNon-randomized trialEfficacy outcome

    In recurrent or metastatic endometrial cancer, 8 leuprolide recipients had stable disease for a median 5 months (range 1-8).

    In plain wordsIn recurrent or metastatic endometrial cancer, 8 leuprolide recipients had stable disease for a median 5 months.

    Peptide
    Leuprolide
    Outcome
    Not applicableStable disease
    Study

    n = 25

    Outcome group
    Tumor growth · Cancer
    Studied dose
    7.5 mg every 28 days · intramuscularAs given in this study (human).

    Measurements

    Patients with stable disease
    8 patients
    25 treated patients
    Stable disease duration, median
    5 months
    patients with stable disease
    Stable disease duration, range
    1 to 8 months
    patients with stable disease

    Source sentences

    Summary
    There were no responders, 8 patients had stable disease for a median 5 months (range 1-8), 14 patients progressed on therapy, and 3 patients were not evaluable for response due to receiving only 1 treatment.
    3 context sentences
    Summary · context
    In order to determine the efficacy and toxicity of the gonadotrophin-releasing hormone agonist Leuprolide in the management of patients with recurrent or metastatic endometrial cancer, we performed a phase II study.
    Summary · context
    Treatment was 7.5 mg i.m. every 28 days, and was to continue for at least 2 courses until evidence of disease progression, patient requested withdrawal, or unacceptable toxicity.
    Summary · context
    Twenty-five patients received Leuprolide for recurrent or metastatic endometrial cancer.
  3. 03HumanNon-randomized trialEfficacy outcome

    In recurrent or metastatic endometrial cancer, 14 patients progressed during leuprolide therapy.

    In plain wordsIn recurrent or metastatic endometrial cancer, 14 patients progressed during leuprolide therapy.

    Peptide
    Leuprolide
    Outcome
    Not applicableDisease progression
    Study

    n = 25

    Outcome group
    Tumor growth · Cancer
    Studied dose
    7.5 mg every 28 days · intramuscularAs given in this study (human).

    Measurements

    Patients who progressed
    14 patients
    25 treated patients

    Source sentences

    Summary
    There were no responders, 8 patients had stable disease for a median 5 months (range 1-8), 14 patients progressed on therapy, and 3 patients were not evaluable for response due to receiving only 1 treatment.
    3 context sentences
    Summary · context
    In order to determine the efficacy and toxicity of the gonadotrophin-releasing hormone agonist Leuprolide in the management of patients with recurrent or metastatic endometrial cancer, we performed a phase II study.
    Summary · context
    Treatment was 7.5 mg i.m. every 28 days, and was to continue for at least 2 courses until evidence of disease progression, patient requested withdrawal, or unacceptable toxicity.
    Summary · context
    Twenty-five patients received Leuprolide for recurrent or metastatic endometrial cancer.
  4. 04HumanNon-randomized trialSafety outcome

    In recurrent or metastatic endometrial cancer, one patient had grade 3 deep venous thrombosis possibly attributable to leuprolide.

    In plain wordsIn recurrent or metastatic endometrial cancer, one patient had severe deep venous thrombosis possibly related to leuprolide.

    Peptide
    Leuprolide
    Outcome
    Not applicableGrade 3 deep venous thrombosis
    Study

    n = 25

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    7.5 mg every 28 days · intramuscularAs given in this study (human).

    Measurements

    Grade 3 toxicity (deep venous thrombosis), possibly attributable
    1 patients
    25 treated patients

    Source sentences

    Summary
    One patient experienced a grade 3 toxicity that was possibly attributable to Leuprolide (deep venous thrombosis).
    3 context sentences
    Summary · context
    In order to determine the efficacy and toxicity of the gonadotrophin-releasing hormone agonist Leuprolide in the management of patients with recurrent or metastatic endometrial cancer, we performed a phase II study.
    Summary · context
    Treatment was 7.5 mg i.m. every 28 days, and was to continue for at least 2 courses until evidence of disease progression, patient requested withdrawal, or unacceptable toxicity.
    Summary · context
    Twenty-five patients received Leuprolide for recurrent or metastatic endometrial cancer.
  5. 05HumanNon-randomized trialEfficacy outcome

    In recurrent or metastatic endometrial cancer treated with leuprolide, median survival from study entry was 6 months.

    In plain wordsIn recurrent or metastatic endometrial cancer treated with leuprolide, median survival from study entry was 6 months.

    Peptide
    Leuprolide
    Outcome
    Not applicableMedian survival
    Study

    n = 25

    Outcome group
    Mortality · Cancer
    Studied dose
    7.5 mg every 28 days · intramuscularAs given in this study (human).

    Measurements

    Median survival from study entry
    6 months
    25 treated patients

    Source sentences

    Summary
    The median survival from study entry was 6 months.
    3 context sentences
    Summary · context
    In order to determine the efficacy and toxicity of the gonadotrophin-releasing hormone agonist Leuprolide in the management of patients with recurrent or metastatic endometrial cancer, we performed a phase II study.
    Summary · context
    Treatment was 7.5 mg i.m. every 28 days, and was to continue for at least 2 courses until evidence of disease progression, patient requested withdrawal, or unacceptable toxicity.
    Summary · context
    Twenty-five patients received Leuprolide for recurrent or metastatic endometrial cancer.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.